AbbVie reported a 12.4% year-over-year increase in Q1 net revenues, showing strong business momentum despite some challenges in its Immunology portfolio. The company raised its full-year 2026 EPS guidance, projecting 14% annual underlying EPS growth after adjusting for IPR&D and milestone expenses. AbbVie is also investing strategically, including a $1.4 billion campus in North Carolina, to support long-term innovation and reduce political risks. These factors suggest confidence in AbbVie's fundamentals and valuation near multiyear lows, making it a buy recommendation.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
